Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $37.7M fell 17.4% year over year, ahead of the -39.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at -12.4% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -17.4% holds above the trailing-twelve-month pace of -39.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 152.81M USD
- Year-over-year change
- -40.9%
- 4-year CAGR
- -8.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 152.81M | -40.9% |
| FY2024 | 2024-12-31 | 258.62M | -13.7% |
| FY2023 | 2023-12-31 | 299.51M | +31.8% |
| FY2022 | 2022-12-31 | 227.29M | +5.0% |
| FY2021 | 2021-12-31 | 216.54M | — |
Operating Expenses vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 operating expenses of $144.89M is the 3rd highest of the 11 companies compared; the peer median is $91.21M.
- Its year-over-year change of -39.4% is the 10th highest of 11, against a peer median of -22.4%.
- Over three fiscal years its annual growth of -12.4% compares with a peer median of +2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $213.41M | -32.3% | +2.0% | 214.2% | |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $144.89M | -39.4% | -12.4% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $122.7M | +143.6% | +40.1% | — |
| LTM Mar 2026 | $118.5M | -49.4% | +2.7% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $91.4M | +21.9% | +10.8% | — |
| LTM Mar 2026 | $91.02M | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $82.81M | -13.0% | -1.4% | 183.7% | |
| LTM Mar 2026 | $54.01M | -31.7% | -36.0% | — | |
| LTM Mar 2026 | $51.84M | -32.4% | +34.1% | 5184.4% | |
| LTM Mar 2026 | $35.95M | +65.2% | +48.4% | — | |
| Peer median (excluding ZNTL) | $91.21M | -22.4% | +2.4% | 199.0% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 67.43M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 67.43M | 0 |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 175.6M | 172.73M | 235.16M | 167.77M | 107.3M |
| Selling, General & Admin | 40.94M | 54.55M | 59.4M | 87.12M | 37.72M |
| Operating Expenses | 216.54M | 227.29M | 299.51M | 258.62M | 152.81M |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| EBITDA | (207.2M) | (233.58M) | (247.6M) | (186.17M) | (144.27M) |
| EBITDA Margin | — | — | — | -276.1% | — |
| Operating Income | (216.54M) | (227.29M) | (299.51M) | (191.19M) | (152.81M) |
| Operating Margin | — | — | — | -283.6% | — |
| Interest Income | 0 | 2.26K | 0 | 0 | 0 |
| Interest Expense | 0 | 2.58M | 0 | 0 | 0 |
| Other Income / Expenses | 50.15M | (10.3M) | 6.6M | 25.5M | 16.19M |
| Income Before Tax | (166.39M) | (237.58M) | (292.91M) | (165.69M) | (136.62M) |
| Pre-Tax Margin | — | — | — | -245.7% | — |
| Income Tax Expense | (297K) | (469K) | (601K) | 177K | 442K |
| Net Income | (158.73M) | (236.81M) | (292.19M) | (165.84M) | (137.06M) |
| Net Margin | — | — | — | -246.0% | — |
| EPS (Basic) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| EPS (Diluted) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) |
| Weighted Avg Shares | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
| Weighted Avg Shares (Diluted) | 42.69M | 52.86M | 65.41M | 71.08M | 71.87M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.